ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

This study — called the ICE Study — tests a combination of three drugs (irinotecan, cetuximab, and envafolimab) as a re-challenge treatment for patients with metastatic colorectal cancer (cancer that has spread) who previously responded to cetuximab or irinotecan but whose cancer later progressed. **You may be eligible if...** - You are 18 years or older - You have been confirmed to have metastatic colorectal adenocarcinoma - Your cancer has specific gene profiles (RAS and BRAF wild-type) confirmed by liquid biopsy - You previously had a complete or partial response to a first-line treatment including cetuximab or irinotecan - It has been more than 2 months since your last cetuximab dose - You have measurable cancer and a good performance status (ECOG 0 or 1) **You may NOT be eligible if...** - You have not previously responded to cetuximab or irinotecan - You have active autoimmune disease - You are pregnant or breastfeeding - You have serious medical conditions affecting your ability to receive treatment Talk to your doctor to see if this trial is right for you.